Financing ·
TransCode pays $840,975 to Yorkville II to waive Amortization Event triggered by stock price falling below $1.72 Floor Price threshold
RNAZTranscode Therapeutics, Inc.
TransCode Therapeutics, Inc. paid $840,975 to Yorkville II PN, Ltd. on October 1, 2026, to waive an Amortization Event triggered by its stock price falling below the $1.72 Floor Price threshold under a Standby Equity Purchase Agreement. The payment covers $759,000 in principal, a $75,900 premium, and accrued interest, reducing the outstanding Convertible Notes balance to approximately $4.1 million. Yorkville waived the event through October 31, 2026, avoiding mandatory monthly amortization payments that would have been calculated as 18% of principal plus additional fees. TransCode Therapeutics operates in the biotechnology industry, focusing on developing RNA-based therapies.